跳至主要内容
临床试验/CTRI/2019/02/017505
CTRI/2019/02/017505尚未招募2 期

Evaluation of efficacy of optimized natural killer cells as an adjunct to allogeneic stem cell transplantation in the treatment of refractory acute myeloid leukemia - ONKAM

Department of Biotechnology India0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Signed and dated written informed consent by start date of Screening visit in accordance with GCP and local legislation
  • Patients with refractory acute myeloid leukemia planned for allogeneic stem cell transplantation
  • Eastern Cooperative Oncology Group (ECOG) performance score <2 at screening
  • Life expectancy of 4 â?? 6 weeks

排除标准

  • Hypersensitivity to chemo drugs
  • Total bilirubin or liver enzymes greater than 3 times the upper limit of normal
  • HIV infection

研究者

发起方
Department of Biotechnology India

相似试验